Actimmune (Interferon Gamma-1B) - Summary

ACTIMMUNE SUMMARY

ACTIMMUNE ^® (Interferon gamma-1b), a biologic response modifier, is a single-chain polypeptide containing 140 amino acids.

ACTIMMUNE is indicated for reducing the frequency and severity of serious infections associated with Chronic Granulomatous Disease.

ACTIMMUNE is indicated for delaying time to disease progression in patients with severe, malignant osteopetrosis.

ACTIMMUNE NEWS HIGHLIGHTS

Published Studies Related to Actimmune (Interferon Gamma-1B)

Randomized phase 3 trial of interferon gamma-1b plus standard carboplatin/paclitaxel versus carboplatin/paclitaxel alone for first-line treatment of advanced ovarian and primary peritoneal carcinomas: results from a prospectively designed analysis of progression-free survival. [2008.05]

Adjuvant interferon gamma in patients with pulmonary atypical Mycobacteriosis: a randomized, double-blind, placebo-controlled study. [2008.02.11]

Final results of a double-blind, placebo-controlled trial of the antifibrotic efficacy of interferon-gamma1b in chronic hepatitis C patients with advanced fibrosis or cirrhosis. [2007.03]

A randomized comparative clinical trial of recombinant canine interferon-gamma (KT-100) in atopic dogs using antihistamine as control. [2006.06]

Randomized, double-blind, placebo-controlled, dose-escalating study of aerosolized interferon gamma-1b in patients with mild to moderate cystic fibrosis lung disease. [2005.03]

more>>

Clinical Trials Related to Actimmune (Interferon Gamma-1B)

Post Marketing Surveillance Study of Actimmune in Patients With Severe, Malignant Osteopetrosis [Completed]

The INSPIRE Trial: A Study of Interferon Gamma-1b for Idiopathic Pulmonary Fibrosis (IPF) [Terminated]

An Open-Label Study of the Safety of Interferon Gamma-1b in Patients With IPF [Terminated]

Safety and Efficacy of Interferon Gamma-1b Plus Chemotherapy for Ovarian and Peritoneal Cancer [Terminated]

Phase I/II Study of Recombinant Human Interferon-Gamma (rIFN-Gamma) in HIV-Infected Children [Completed]

more>>